Pomerantz Law Firm Informs Investors of Class Action Against Replimune Group, Inc.

Pomerantz Law Firm Warns Investors of Class Action Suit Against Replimune Group, Inc.

On August 13, 2026, the Pomerantz Law Firm announced that a class action lawsuit has been initiated against Replimune Group, Inc. (NASDAQ: REPL). This legal action has been spurred by allegations of possible securities fraud and other unlawful business practices committed by Replimune and certain executives.

The firm is actively seeking to engage investors who have suffered losses from their investments in Replimune and is inviting them to reach out to Danielle Peyton at Pomerantz for further assistance. Investors can connect via email at [email protected] or by phone at 646-581-9980. Inquiries should ideally include a complete mailing address, telephone number, and details regarding the number of shares acquired.

The class action filing centers on the company's failure to disclose pertinent information that could impact investor decisions. It particularly arises from events on April 10, 2026, when the FDA issued a Complete Response Letter (CRL) rejecting Replimune’s Biologics License Application (BLA) for RP1 in combination with nivolumab. The rejection pointed out significant deficiencies in the clinical studies conducted, notably RPL-001-16 and RP1-104. The letter stated, "the evidence as presented does not meet the evidentiary standards required for regulatory approval."

In light of this news, Replimune’s stock took a heavy hit, plummeting by $1.15, or 19.46%, closing at $4.76 on April 10. As news developed, the company issued a release indicating that while the FDA suggested a randomized controlled trial may be necessary, they also alluded to the possibility of a single-arm trial if sufficiently compelling data were presented. This led to further declines in the stock price, which fell dramatically by $3.06, or 64.29%, with shares closing at $1.70 on April 13.

Investors involved during the designated Class Period, who wish to assume the role of Lead Plaintiff, must act before the approaching deadline of October 5, 2026. For detailed information on joining the class action, interested parties are encouraged to review the Complaint available at www.pomerantzlaw.com.

Pomerantz LLP has established itself as a leading firm in class action and securities litigation, with a reputation steered by its founding figure, Abraham L. Pomerantz. With over 85 years of experience, the team fights for the rights of victims affected by securities fraud and corporate wrongdoings, having secured numerous multimillion-dollar settlements on behalf of its class members.

In light of these developments, investors and market watchers alike are advised to stay informed regarding the potential implications of this class action lawsuit on Replimune Group, Inc.

Note: This article is for informational purposes only and should not be considered as investment advice. Prior results by Pomerantz do not guarantee similar outcomes for all cases.